Ipidacrine
Clinical data | |
---|---|
Trade names | Neiromidin |
Synonyms | Amiridine; NIK-247 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C12H16N2 |
Molar mass | 188.27 g/mol |
3D model (JSmol) | |
| |
|
WikiDoc Resources for Ipidacrine |
Articles |
---|
Most recent articles on Ipidacrine |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Ipidacrine at Clinical Trials.gov Clinical Trials on Ipidacrine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Ipidacrine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Ipidacrine Discussion groups on Ipidacrine Patient Handouts on Ipidacrine Directions to Hospitals Treating Ipidacrine Risk calculators and risk factors for Ipidacrine
|
Healthcare Provider Resources |
Causes & Risk Factors for Ipidacrine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ipidacrine (Neiromidin) is a novel substance synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. This compound contains the structure of 4-aminopyridine and is structurally very similar to tacrine.[1]
Ipidacrine is a reversible acetylcholinesterase inhibitor used in memory disorders of different origins.[2][3][4]
Ipidacrine directly stimulates impulse transmission in the CNS and neuromuscular synapses by blocking membrane potassium channels. Neiromidin enhances not only choline, but also adrenaline, serotonin, histamine and oxytocin effects on smooth muscle.[5]
References
- ↑ Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio (1998). "Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent". CNS Drug Reviews. 4 (3): 247. doi:10.1111/j.1527-3458.1998.tb00067.x.
- ↑ Damulin, IV; Stepkina, DA; Lokshina, AB (2011). "Neuromidin in mixed vascular and Alzheimer's dementia". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (2): 40–3. PMID 21350422.
- ↑ Pustokhanova, LV; Morozova, EM (2011). "Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (4 Pt 2): 23–7. PMID 23120773.
- ↑ Onodera, K; Kojima, J; Wachi, M (1998). "Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task". Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. 18 (2): 33–7. PMID 9656230.
- ↑ Neiromidin Product Information
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles with non-default infobox title
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Pyridines
- Drug